Dipraglurant

Drug Profile

Dipraglurant

Alternative Names: ADX 48621; Dipraglurant-ER; Dipraglurant-MR

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics
  • Class Alkynes; Heterocyclic bicyclo compounds; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Anxiety disorders; Drug-induced dyskinesia; Dystonia; Major depressive disorder

Highest Development Phases

  • Phase II Drug-induced dyskinesia
  • Phase I Dystonia; Torticollis
  • Preclinical Major depressive disorder
  • Discontinued Anxiety disorders

Most Recent Events

  • 02 Jun 2016 Interim adverse events data from a phase IIa trial in Drug-induced dyskinesia released by Addex Therapeutics
  • 11 Apr 2016 Pharmacodynamics and pharmacokinetics data from a phase I trial in healthy volunteers released by Addex Therapeutics
  • 15 Mar 2016 Adverse events data from a phase I trial in healthy volunteers released by Addex Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top